ZBIOZenas BioPharma, Inc.

$33.10

$15.2052 weeks$43.17

Price

$33.10+92%1Y

1M+2.8%1Y+92%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average

6/10

Value79

Quality6

Momentum68

Growth-

Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an I&I focused biopharmaceutical company. Our core business strategy combines disciplined product candidate acquisition with strategic deployment of internal expertise and effective use of external resources.

In the company’s own words · 10-K filed Mar 16, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$1.56B

1Y Return+92%

5Y Return-

For the full year FY2025, revenue was $10M (+100% year on year) and net income −$378M.